152 related articles for article (PubMed ID: 30882020)
1. Cerebellar syndrome in a man treated with natalizumab: From the National Multiple Sclerosis Society Case Conference Proceedings.
Lapides DA; Batchala PP; Donahue JH; Lisak RP; Meltzer EI; Narayan RN; Nath A; Frohman TC; Costello K; Goldman MD; Zamvil SS; Frohman EM
Neurol Neuroimmunol Neuroinflamm; 2019 May; 6(3):e546. PubMed ID: 30882020
[No Abstract] [Full Text] [Related]
2. Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy.
Warnke C; Wijburg MT; Hartung HP; Killestein J; Adams O; Wattjes MP
J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1092-1094. PubMed ID: 28490505
[No Abstract] [Full Text] [Related]
3. Fatal natalizumab-associated progressive multifocal leukoencephalopathy with initial low JCV antibody index in a multiple sclerosis patient.
Hay M; Leguy S; Cahagne V; Lassalle N; Le Page E; Michel L
Rev Neurol (Paris); 2024 Jun; 180(6):565-567. PubMed ID: 38429158
[No Abstract] [Full Text] [Related]
4. Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
Bacchetta F; Mathias A; Schluep M; Du Pasquier R
Mult Scler; 2017 Feb; 23(2):300-303. PubMed ID: 28165319
[TBL] [Abstract][Full Text] [Related]
5. JC viremia in natalizumab-treated patients with multiple sclerosis.
Major EO; Frohman E; Douek D
N Engl J Med; 2013 Jun; 368(23):2240-1. PubMed ID: 23738566
[No Abstract] [Full Text] [Related]
6. Considerations for characterizing the risk of PML in natalizumab-treated patients.
Koendgen H; Ho PR; Chang I
Mult Scler Relat Disord; 2016 Sep; 9():121. PubMed ID: 27645357
[No Abstract] [Full Text] [Related]
7. Progressive multifocal leukoencephalopathy and granule cell neuronopathy with novel mutation flanking VP1 C-terminus in natalizumab-extended interval dosing.
Rempe T; Wang Q; Wu Q; Ballur Narayana Reddy V; Newcomer Z; Miravalle A; Mao-Draayer Y
Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32198230
[No Abstract] [Full Text] [Related]
8. Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification.
Pitarokoili K; Gold R
Nat Rev Neurol; 2017 Dec; 13(12):710-712. PubMed ID: 29146954
[No Abstract] [Full Text] [Related]
9. Quantitative electroencephalography supports diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.
Classen G; Classen C; Bernasconi C; Brandt C; Gold R; Chan A; Hoepner R
J Neurovirol; 2019 Feb; 25(1):133-136. PubMed ID: 30414049
[TBL] [Abstract][Full Text] [Related]
10. Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay.
Gagne Brosseau MS; Stobbe G; Wundes A
Neurology; 2016 Feb; 86(5):484-6. PubMed ID: 26740679
[No Abstract] [Full Text] [Related]
11. High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - YES.
Yap SM; McGuigan C
Mult Scler; 2017 May; 23(6):765-767. PubMed ID: 28287039
[No Abstract] [Full Text] [Related]
12. Natalizumab risk stratification: role of a two- step anti-JCV antibody assay.
O'Connor PW
Can J Neurol Sci; 2012 Sep; 39(5):670-5. PubMed ID: 22931715
[No Abstract] [Full Text] [Related]
13. More on JC viremia in natalizumab-treated patients with multiple sclerosis.
Subramanyam M; Belachew S; Compton T
N Engl J Med; 2013 Sep; 369(13):1279-80. PubMed ID: 24066762
[No Abstract] [Full Text] [Related]
14. More on JC viremia in natalizumab-treated patients with multiple sclerosis.
Major EO; Frohman E; Douek D
N Engl J Med; 2013 Sep; 369(13):1280. PubMed ID: 24066761
[No Abstract] [Full Text] [Related]
15. PML in natalizumab-treated multiple sclerosis: Modeling errors and risk miscalculations.
Mowry EM; McArthur JC
Neurology; 2017 Mar; 88(12):1110-1111. PubMed ID: 28228562
[No Abstract] [Full Text] [Related]
16. Holmes tremor caused by a natalizumab-related progressive multifocal leukoencephalopathy: a case report and brief review of the literature.
Magistrelli L; Vecchio D; Naldi P; Comi C; Cantello R
Neurol Sci; 2019 Sep; 40(9):1943-1945. PubMed ID: 30825017
[No Abstract] [Full Text] [Related]
17. CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.
Pignolet B; Schwab N; Schneider-Hohendorf T; Bucciarelli F; Biotti D; Averseng-Peaureaux D; Outteryck O; Ongagna JC; de Sèze J; Brochet B; Ouallet JC; Debouverie M; Pittion S; Defer G; Derache N; Hautecoeur P; Tourbah A; Labauge P; Castelnovo G; Clavelou P; Berger E; Pelletier J; Rico A; Zéphir H; Laplaud D; Wiertlewski S; Camu W; Thouvenot E; Casez O; Moreau T; Fromont A; Vukusic S; Papeix C; Vermersch P; Comabella M; Lebrun-Frenay C; Wiendl H; Brassat D;
Neurology; 2016 Dec; 87(23):2491-2494. PubMed ID: 27815407
[No Abstract] [Full Text] [Related]
18. Neurological complications of infliximab.
Roos JC; Ostor AJ
J Rheumatol; 2007 Jan; 34(1):236-7; author reply 237-8. PubMed ID: 17216699
[No Abstract] [Full Text] [Related]
19. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
Reuwer AQ; Heron M; van der Dussen D; Schneider-Hohendorf T; Murk JL
Acta Neurol Scand; 2017 Nov; 136 Suppl 201():37-44. PubMed ID: 29068484
[TBL] [Abstract][Full Text] [Related]
20. Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks.
Maloney E; Molloy A; Al Hussona M; O'Donnell L; Killeen R; McGuigan C
J Neurol; 2017 Feb; 264(2):401-403. PubMed ID: 28039520
[No Abstract] [Full Text] [Related]
[Next] [New Search]
